Origo Biopharma closes EUR 2.3m funding round

We participate in the process by which Origo Biopharma, a Spain-based startup, closed a EUR 2.3m funding round, subscribed by Sabadell Asabys, Xesgalicia, and the company's current investors.  

Origo Biopharma, based in San Cibrao de Viñas, Ourense, is a biotech company specializing in the research and development of immunotherapeutic products that address health disorders related to TGF-β signaling dysfunction, among these, cancer and fibrosis.  With the transaction, the company covers the financial needs to complete the preclinical development and initiate the first clinical studies of its drug for the treatment of patients with fibrosis associated with Crohn's disease, as well as to advance its programs in Idiopathic Pulmonary Fibrosis and colorectal cancer.